journal
MENU ▼
Read by QxMD icon Read
search

Pharmacogenomics

journal
https://www.readbyqxmd.com/read/28481161/corrigendum
#1
(no author information available yet)
No abstract text is available yet for this article.
May 8, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28480819/should-a-routine-genotyping-of-cyp2d6-and-cyp2c19-genetic-polymorphisms-be-recommended-to-predict-venlafaxine-efficacy-in-depressed-patients-treated-in-psychiatric-settings
#2
Adela Taranu, Romain Colle, Florence Gressier, Khalil El Asmar, Laurent Becquemont, Emmanuelle Corruble, Céline Verstuyft
AIM: The antidepressant venlafaxine (VEN) is metabolized by CYP2D6 and CYP2C19. The aim of this study was to assess the relevance of generalizing to daily practice the genotyping of CYP2D6 and CYP2C19 to predict VEN efficacy in depressed patients treated in psychiatric settings. PATIENTS & METHODS: This study was nested in a naturalistic cohort, with 206 patients requiring a new antidepressant treatment and genotyped for CYP2D6 *3, *4, *5 del, *6, *2xN, *10, *41 and CYP2C19 *2, *3, *4, *5, *17 alleles...
May 8, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28480783/pharmacogenetics-of-drug-drug-interaction-and-drug-drug-gene-interaction-a-systematic-review-on-cyp2c9-cyp2c19-and-cyp2d6
#3
Muh Akbar Bahar, Didik Setiawan, Eelko Hak, Bob Wilffert
Currently, most guidelines on drug-drug interaction (DDI) neither consider the potential effect of genetic polymorphism in the strength of the interaction nor do they account for the complex interaction caused by the combination of DDI and drug-gene interaction (DGI) where there are multiple biotransformation pathways, which is referred to as drug-drug-gene interaction (DDGI). In this systematic review, we report the impact of pharmacogenetics on DDI and DDGI in which three major drug-metabolizing enzymes - CYP2C9, CYP2C19 and CYP2D6 - are central...
May 8, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28470127/polymorphisms-associated-with-etanercept-response-in-moderate-to-severe-plaque-psoriasis
#4
María C Ovejero-Benito, Rocío Prieto-Pérez, Mar Llamas-Velasco, Carmen Belmonte, Teresa Cabaleiro, Manuel Román, Dolores Ochoa, María Talegón, Miriam Saiz-Rodríguez, Esteban Daudén, Francisco Abad-Santos
AIM: Few studies have evaluated the influence of pharmacogenetics in psoriatic patients treated with etanercept. MATERIALS & METHODS: We evaluated the association between 124 polymorphisms with the response to etanercept in patients with moderate-to-severe plaque psoriasis at 3 months (n = 78) and 6 months of treatment (n = 68). RESULTS: The results of the multivariate analysis showed an association between polymorphisms rs13437088 (HLA-B/MICA), rs96844 (MAP3K1), rs2431697 (PTTG1), rs9304742 (ZNF816A) and the response to etanercept at 3 months...
May 4, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28470112/sequencing-the-cyp2d6-gene-from-variant-allele-discovery-to-clinical-pharmacogenetic-testing
#5
Yao Yang, Mariana R Botton, Erick R Scott, Stuart A Scott
CYP2D6 is one of the most studied enzymes in the field of pharmacogenetics. The CYP2D6 gene is highly polymorphic with over 100 catalogued star (*) alleles, and clinical CYP2D6 testing is increasingly accessible and supported by practice guidelines. However, the degree of variation at the CYP2D6 locus and homology with its pseudogenes make interrogating CYP2D6 by short-read sequencing challenging. Moreover, accurate prediction of CYP2D6 metabolizer status necessitates analysis of duplicated alleles when an increased copy number is detected...
May 4, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28470111/serum-clomipramine-and-desmethylclomipramine-levels-in-a-cyp2c19-and-cyp2d6-intermediate-metabolizer
#6
Jacob T Brown, Mark Schneiderhan, Seenae Eum, Jeffrey R Bishop
Pharmacogenetics within psychiatry has the potential to aid in the dose and selection of medications. A substantial number of psychiatric medications are metabolized through either of the highly polymorphic drug-metabolizing enzymes CYP2D6 and CYP2C19. Of these, clomipramine is subject to metabolism by both CYP2C19 and CYP2D6, leaving individuals with deficiencies of these drug-metabolizing enzymes at risk of higher concentrations of the parent molecule. Herein, we present the case of a 29-year-old male with diagnoses of depression and obsessive compulsive disorder who had trialed and failed a dozen psychiatric medications, many of which are subject to metabolism by CYP2D6 and/or CYP2C19, and had most recently been taking clomipramine for approximately 2...
May 4, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28470107/cyp450-genotype-and-aggressive-behavior-on-selective-serotonin-reuptake-inhibitors
#7
Corine Ekhart, Maja Matic, Agnes Kant, Eugène van Puijenbroek, Ron van Schaik
AIM: Genetic variants for selective serotonin reuptake inhibitor (SSRI) metabolizing enzymes have been hypothesized to be a risk factor for aggression as adverse drug effect of SSRIs. Our aim was to assess the possible involvement of these polymorphisms on aggression when using SSRIs. MATERIALS & METHODS: A retrospective noninterventional case-control study was performed on 18 cases. The genetic profile of two main genes involved in the metabolism of SSRIs was determined, and predicted phenotype frequencies were compared with Dutch controls and literature data...
May 4, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28470102/oct1-genetic-variants-are-associated-with-postoperative-morphine-related-adverse-effects-in-children
#8
Rajiv Balyan, Xue Zhang, Vidya Chidambaran, Lisa J Martin, Tomoyuki Mizuno, Tsuyoshi Fukuda, Alexander A Vinks, Senthilkumar Sadhasivam
AIM: Large interindividual variability in morphine pharmacokinetics (PK) could contribute to variability in morphine analgesia and adverse events. Respiratory depression (RD) and postoperative nausea and vomiting (PONV) are significant adverse drug response of intravenous morphine in the perioperative setting limiting its efficacy in achieving adequate surgical pain relief. OCT1 is a transporter in the liver that transports morphine from the bloodstream into hepatocytes. Earlier we reported association of genetic polymorphisms in OCT1 with morphine PK, and lower morphine clearance in Caucasian children as compared with African-American (AA) children...
May 4, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28468529/pharmacogenomics-in-pediatric-acute-lymphoblastic-leukemia-promises-and-limitations
#9
Zeina N Al-Mahayri, George P Patrinos, Bassam R Ali
Despite the significant advances achieved in pediatric acute lymphocytic leukemia (ALL) treatment, adverse side effects of drugs remain a challenging issue. Numerous ALL pharmacogenomic studies have been conducted to elucidate the predisposing genetic factors for their development. Plausible pharmacogenomic data are available for the osteonecrosis associated with glucocorticoids, the neurotoxicity associated with vincristine and the cardiotoxicity related to anthracyclines. However, these data have not been fully translated into the clinic due to several limitations, most importantly the lack of reliable evidence...
May 4, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28468521/understanding-cancer-lineage-plasticity-reversing-therapeutic-resistance-in-metastatic-prostate-cancer
#10
Leigh Ellis
No abstract text is available yet for this article.
May 4, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28453396/pharmacogenetic-analysis-of-hepatitis-c-virus-related-mixed-cryoglobulinemia
#11
Jessica Cusato, Lucio Boglione, Amedeo De Nicolò, Chiara Simona Cardellino, Chiara Carcieri, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio
AIM: Mixed cryoglobulinemia (MC) is an extra hepatic hepatitis C virus related problem and different studies suggested genetics' role in predicting this complication. We evaluated the influence of SNPs in IL-28B, SLC29A1, SLC28A2, NT5C2, HNF4 and ABCB1 genes in MC prediction. PATIENTS & METHODS: SNPs were evaluated through real-time PCR. RESULTS:  ABCB1 (gene encoding P-glycoprotein) 3435C>T SNP was associated with MC presence (p = 0.034): related to T allele carriers (CC vs CT/TT), we reached a p-value of 0...
April 28, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28453395/association-of-vitamin-d-pathway-snps-and-clinical-response-to-interferon-in-a-cohort-of-hbeag-negative-patients
#12
Jessica Cusato, Lucio Boglione, Amedeo De Nicolò, Rosaria Imbornone, Chiara Simona Cardellino, Valeria Ghisetti, Chiara Carcieri, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio
AIM: Vitamin D modulates biological processes; an influence of vitamin D levels and genetic variants was identified concerning hepatitis B virus infection. We evaluated the role of some SNPs of vitamin D pathway genes in some clinical features of hepatitis B affected patients treated with pegylated interferon. METHODS: We investigated SNPs in IL-28B, CYP27B1, CYP27A1, CYP24A1, VDBP and VDR genes, through real-time PCR. RESULTS:  VDRApaI SNP was associated to viral load and HBsAg presence at different timings...
April 28, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28453389/gwas-analysis-of-treatment-resistant-schizophrenia-interaction-effect-of-childhood-trauma
#13
Arthur Koga, Ali Bani-Fatemi, Nuwan Hettige, Carol Borlido, Clement Zai, John Strauss, Philip Gerretsen, Ariel Graff, Gary Remington, Vincenzo De Luca
AIMS: In the current study, we aimed to compare the prevalence of adverse lifetime events in treatment resistant and non-treatment resistant schizophrenia in a genome-wide association study. MATERIALS & METHODS: Our sample consisted of 84 Caucasian participants with schizophrenia spectrum disorders, assessed cross-sectionally to collect information regarding drug effectiveness and childhood trauma. Using a genome-wide association analysis, we tested single-nucleotide polymorphisms for their association with resistance to antipsychotics defined according to American Psychiatric Association criteria...
April 28, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28358601/pharmacogenetics-in-the-treatment-of-pre-eclampsia-current-findings-challenges-and-perspectives
#14
Marcelo R Luizon, Ana Ct Palei, Ricardo C Cavalli, Valeria C Sandrim
Pre-eclampsia (PE) is defined as pregnancy-induced hypertension and proteinuria, and is a major cause of maternal and perinatal morbidity and mortality. A large subgroup of pregnant women with PE is nonresponsive to antihypertensive drugs, including methyldopa, nifedipine and hydralazine. Pharmacogenomics may help to guide the individualized therapy for this nonresponsive subgroup. However, just a few pharmacogenetic studies examined the effects of genetic polymorphisms on response to antihypertensive drugs in PE, and the criteria of responsiveness used to define responsive or nonresponsive subgroups to antihypertensive therapy should be replicated by others...
March 30, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28358597/common-genetic-polymorphisms-of-adenosine-a2a-receptor-do-not-influence-response-to-regadenoson
#15
Mark Berlacher, Ronald Mastouri, Santosh Philips, Todd C Skaar, Rolf P Kreutz
AIM: Hemodynamic response to regadenoson varies greatly, and underlying mechanisms for variability are poorly understood. We hypothesized that five common variants of adenosine A2A receptor (ADORA2A) are associated with altered response to regadenoson. METHODS: Consecutive subjects (n = 357) undergoing resting regadenoson nuclear stress imaging were enrolled. Genotyping was performed using Taqman-based assays for rs5751862, rs229838, rs3761422, rs2267076 and rs5751876...
March 30, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28353407/replicated-evidence-for-aminoacylase-3-and-nephrin-gene-variations-to-predict-antihypertensive-drug-responses
#16
Jenni M Rimpelä, Kimmo K Kontula, Frej Fyhrquist, Kati M Donner, Annukka M Tuiskula, Antti-Pekka Sarin, Robert P Mohney, Steven M Stirdivant, Timo P Hiltunen
AIM: To replicate the genome-wide associations of the antihypertensive effects of bisoprolol and losartan in GENRES, using the Finnish patients of LIFE study. PATIENTS & METHODS: We analyzed association of four SNPs with atenolol and three SNPs with losartan response in 927 Finnish LIFE patients (467 for atenolol and 460 for losartan). RESULTS: rs2514036, a variation at a transcription start site of ACY3, was associated with blood pressure response to atenolol in men in LIFE...
March 29, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28346074/germline-genetic-predictors-of-aromatase-inhibitor-concentrations-estrogen-suppression-and-drug-efficacy-and-toxicity-in-breast-cancer-patients
#17
Daniel L Hertz, N Lynn Henry, James M Rae
The third-generation aromatase inhibitors (AIs), anastrozole, letrozole and exemestane, are highly effective for the treatment of estrogen receptor-positive breast cancer in postmenopausal women. AIs inhibit the aromatase (CYP19A1)-mediated production of estrogens. Most patients taking AIs achieve undetectable blood estrogen concentrations resulting in drug efficacy with tolerable side effects. However, some patients have suboptimal outcomes, which may be due, in part, to inherited germline genetic variants...
March 27, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28346059/deferasirox-pharmacogenetic-influence-on-pharmacokinetic-efficacy-and-toxicity-in-a-cohort-of-pediatric-patients
#18
Sarah Allegra, Silvia De Francia, Jessica Cusato, Arianna Arduino, Davide Massano, Filomena Longo, Antonio Piga, Antonio D'Avolio
AIM: We aimed to evaluate the influence of genetic polymorphisms involved in deferasirox metabolism and transport on its pharmacokinetics and treatment toxicity, in a cohort of β-thalassaemic children. PATIENTS & METHODS: Drug plasma concentrations were measured by a HPLC-UV method. Allelic discrimination for UGT1A1, UGT1A3, CYP1A1, CYP1A2, CYP2D6, MRP2 and BCRP1 polymorphisms was performed by real-time PCR. RESULTS: CYP1A1 rs2606345AA influenced Ctrough (p = 0...
March 27, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28346057/the-role-of-germline-variants-in-chemotherapy-outcome-in-brain-tumors-a-systematic-review-of-pharmacogenetic-studies
#19
Marije J Klumpers, Marieke Jh Coenen, Corrie Em Gidding, D Maroeska Wm Te Loo
AIM: This systematic review provides an overview of publications concerning pharmacogenetic research in pediatric patients with medulloblastoma and low-grade glioma. MATERIALS & METHODS: Three electronic databases searches including a manual search were performed to identify studies investigating potential interactions between germline variants and chemotherapy efficacy and toxicity. RESULTS: Out of 3570 citations, 21 studies were included...
March 27, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28290774/multimorbidity-polypharmacy-and-pharmacogenomics-in-old-age
#20
Jürgen Brockmöller, Julia C Stingl
No abstract text is available yet for this article.
March 14, 2017: Pharmacogenomics
journal
journal
34814
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"